Bausch + Lomb Corp

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bausch + Lomb Corp reports stellar Q2 performance and raises guidance

Bausch + Lomb Corp's Q2 2024 earnings call showcased robust performance, with revenue growth, margin improvement, and raised guidance reflecting a strong outlook.
The company's emphasis on innovation, operational excellence, and long-term growth strategies highlights a commitment to sustained success and shareholder value.
While facing challenges in specific areas and competitive markets, Bausch + Lomb's focus on balancing growth, margins, and investments positions it well for future opportunities.

Bausch + Lomb Corp (BLCO) reports strong Q3 earnings and raises full-year guidance amidst strategic growth focus

Bausch + Lomb Corp (BLCO) delivered a strong Q3 performance with revenue growth, margin expansion, and raised full-year guidance, reflecting a solid financial outlook.
The company's focus on execution, product launches, and strategic investments is driving growth and profitability across segments, showcasing a resilient business strategy.
While challenges like market dynamics and operational complexities persist, opportunities in market expansion, innovation, and strategic partnerships offer avenues for sustained growth.
Overall, Bausch + Lomb Corp (BLCO) is well-positioned for continued success through its commitment to growth, innovation, and operational excellence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch + Lomb Corp. priced its IPO at $18 a share Thursday, falling short of expectations as it became the first big company in months to try going public into a turbulent stock market.

Bausch + Lomb prices IPO at $18 a share, below expectations

LAVAL, QC and VAUGHAN, ON, May 5, 2022 /PRNewswire/ -- Bausch + Lomb Corporation ("Bausch + Lomb"), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the pricing of its initial public offering ("IPO") of 35,000,000 common shares at a public offering price of $18.00 per share. A wholly owned subsidiary of Bausch Health (the "Selling Shareholder") is offering all of the common shares, and Bausch + Lomb will not receive any of the proceeds from the IPO.

Bausch + Lomb Corporation Announces Pricing of IPO

Bausch + Lomb Corp. BLCO,  priced its IPO at $18 a share Thursday, falling short of expectations as it became the first big company in months to try going public into a turbulent stock market.

The Wall Street Journal: Bausch + Lomb prices IPO at $18 a share, below expectations

In a move that highlights the constraints of the current market, eye care company Bausch + Lomb will likely price its initial public offering (IPO) at the low end of expectations, The Wall Street Journal wrote Thursday (May 5). The report said bankers involved in the deal have told investors that the stock will be […]

Bausch + Lomb's IPO Will Likely be Priced Below Expectations

The number of traditional IPOs so far this year has plunged 74% to just 35 companies, raising about $3.2 billion, according to Dealogic.

Bausch + Lomb Headlines the IPO Market This Week

Bausch Health Companies Inc

Bausch + Lomb, a well-known leader in eye care, is about to hit Wall Street in what investment bankers almost certainly hope will jump-start a weak initial public offering (IPO) market. Bausch Health Companies (BHC) is a global healthcare stock that develops pharmaceuticals, medical devices and over-the-counter medications, with focus areas in eye health, gastroenterology and dermatology.

Bausch + Lomb IPO: What You Need to Know

Here's what investors may want to know about the upcoming BLCO stock IPO, as Bausch + Lomb is split off from its parent company this week. The post BLCO Stock IPO: When Does Bausch + Lomb Go Public?

BLCO Stock IPO: When Does Bausch + Lomb Go Public? What Is the Bausch + Lomb IPO Price Range?

The U.S. initial public offering market is bracing for what is expected to be the second-biggest deal of the year so far this week, that of eyecare company Bausch & Lomb, which is expected to raise up to $840 million at a valuation of more than $8 billion.

IPO Report: U.S. IPO market bracing for second-biggest deal of the year so far in eyecare health company Bausch + Lomb

Bausch + Lomb has filed proposed terms for a $788 million IPO. The firm develops and sells contact lens and other eyecare products worldwide.

Bausch + Lomb Targets $788 Million IPO

The well-known eye-health brand has filed to sell 35 million shares at $21 to $24 each, according to a prospectus.

Bausch + Lomb Targets $8.4 Billion Valuation with IPO

Rail Vision Ltd

Expion360 Inc

The 1Q22 IPO market ended with another quiet week. Just two SPACs priced.

U.S. IPO Weekly Recap: The Q122 IPO Market Closes Out With SPACs And Pipeline News

Global IPO volumes fell 37% during the first quarter of 2022 according to a study from EY.

Bausch & Lomb Files for IPO as Global Listing Volumes Slump

News for Bausch + Lomb Corp Stock (BLCO)